These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

690 related items for PubMed ID: 7522954

  • 1. Independent expression of p55 and p75 interleukin-2 receptors (IL-2R) during intravenous or subcutaneous administration of recombinant interleukin-2 (rIL-2) by T-lymphocytes and natural killer cells.
    Zambello R, Trentin L, Cerutti A, Enthammer C, Milani A, Franceschi T, Messina C, Cetto GL, Agostini C, Semenzato G.
    Cancer; 1994 Nov 01; 74(9):2562-9. PubMed ID: 7522954
    [Abstract] [Full Text] [Related]

  • 2. Activation of the immune system of cancer patients by continuous i.v. recombinant IL-2 (rIL-2) therapy is dependent on dose and schedule of rIL-2.
    Gratama JW, Bruin RJ, Lamers CH, Oosterom R, Braakman E, Stoter G, Bolhuis RL.
    Clin Exp Immunol; 1993 May 01; 92(2):185-93. PubMed ID: 8485906
    [Abstract] [Full Text] [Related]

  • 3. Different mechanisms of activation of proliferating CD3+ cells in patients with lymphoproliferative disease of granular lymphocytes.
    Zambello R, Cassatella MA, Trentin L, Bulian P, Siviero F, Feruglio C, Agostini C, Vespignani M, Chisesi T, Pizzolo G.
    Leukemia; 1991 Nov 01; 5(11):942-50. PubMed ID: 1835747
    [Abstract] [Full Text] [Related]

  • 4. Selective modulation of human natural killer cells in vivo after prolonged infusion of low dose recombinant interleukin 2.
    Caligiuri MA, Murray C, Robertson MJ, Wang E, Cochran K, Cameron C, Schow P, Ross ME, Klumpp TR, Soiffer RJ.
    J Clin Invest; 1993 Jan 01; 91(1):123-32. PubMed ID: 7678599
    [Abstract] [Full Text] [Related]

  • 5. Expression of p75 chain of IL-2 receptor in the early immunological reconstitution after allogeneic bone marrow transplantation.
    Comoli P, Maccario R, Montagna D, Labirio M, Zecca M, Clementi R, Bonetti F, Locatelli F.
    Clin Exp Immunol; 1994 Sep 01; 97(3):510-6. PubMed ID: 8082308
    [Abstract] [Full Text] [Related]

  • 6. HLA-Dr-expressing CD8bright cells are only temporarily present in the circulation during subcutaneous recombinant interleukin-2 therapy in renal cell carcinoma patients.
    Janssen RA, Buter J, Straatsma E, Heijn AA, Sleijfer DT, de Vries EG, Mulder NH, The TH, de Leij L.
    Cancer Immunol Immunother; 1993 Sep 01; 36(3):198-204. PubMed ID: 8439981
    [Abstract] [Full Text] [Related]

  • 7. Effects of escalating doses of recombinant human interleukin-2 in correcting functional T-cell defects following autologous bone marrow transplantation for lymphomas and solid tumors.
    Bosly A, Guillaume T, Brice P, Humblet Y, Staquet P, Doyen C, Chatelain B, Franks CR, Gisselbrecht C, Symann M.
    Exp Hematol; 1992 Sep 01; 20(8):962-8. PubMed ID: 1354620
    [Abstract] [Full Text] [Related]

  • 8. Functional p75 interleukin-2 receptor expression on the fresh blast cells in childhood acute lymphoblastic leukemia with natural killer cell properties.
    Ichikawa M, Kawai H, Komiyama A, Tsudo M, Miyasaka M, Kinoshita A, Nakazawa S.
    Am J Hematol; 1991 Apr 01; 36(4):259-64. PubMed ID: 2012073
    [Abstract] [Full Text] [Related]

  • 9. Low-dose interleukin-2 in combination with interferon-alpha effectively modulates biological response in vivo.
    Schneekloth C, Körfer A, Hadam M, Lopez Hänninen E, Menzel T, Schomburg A, Dallmann I, Kirchner H, Poliwoda H, Atzpodien J.
    Acta Haematol; 1993 Apr 01; 89(1):13-21. PubMed ID: 7683166
    [Abstract] [Full Text] [Related]

  • 10. Interleukin (IL) 15 is a novel cytokine that activates human natural killer cells via components of the IL-2 receptor.
    Carson WE, Giri JG, Lindemann MJ, Linett ML, Ahdieh M, Paxton R, Anderson D, Eisenmann J, Grabstein K, Caligiuri MA.
    J Exp Med; 1994 Oct 01; 180(4):1395-403. PubMed ID: 7523571
    [Abstract] [Full Text] [Related]

  • 11. Progression of natural immunity during one-year treatment of residual disease in neuroblastoma patients with high doses of interleukin-2 after autologous bone marrow transplantation.
    Martí F, Pardo N, Peiró M, Bertran E, Amill B, García J, Cubells J, Rueda F.
    Exp Hematol; 1995 Dec 01; 23(14):1445-52. PubMed ID: 8542930
    [Abstract] [Full Text] [Related]

  • 12. Expansion of peripheral blood natural killer cells correlates with clinical outcome in cancer patients receiving recombinant subcutaneous interleukin-2 and interferon-alpha-2.
    Atzpodien J, Kirchner H, Körfer A, Hadam M, Schomburg A, Menzel T, Deckert M, Franzke A, Volkenandt M, Dallmann I.
    Tumour Biol; 1993 Dec 01; 14(6):354-9. PubMed ID: 8265981
    [Abstract] [Full Text] [Related]

  • 13. Anti-CD3 antibody-induced expression of both p55 and p75 chains of the high affinity interleukin-2 receptor on human T lymphocytes is inhibited by cyclosporin A.
    Foxwell BM, Simon J, Herrero JJ, Taylor D, Woerly G, Cantrell D, Ryffel B.
    Immunology; 1990 Jan 01; 69(1):104-9. PubMed ID: 2312149
    [Abstract] [Full Text] [Related]

  • 14. Differential responses to interleukin 2 define functionally distinct subsets of human natural killer cells.
    Baume DM, Robertson MJ, Levine H, Manley TJ, Schow PW, Ritz J.
    Eur J Immunol; 1992 Jan 01; 22(1):1-6. PubMed ID: 1370410
    [Abstract] [Full Text] [Related]

  • 15. Phorbol myristate acetate-induced expression of high-affinity interleukin 2 receptors and production of interleukin 2 by human acute lymphoblastic leukemia T cells.
    Sahraoui Y, Allouche M, Perrakis M, Clemenceau C, Jasmin C, Georgoulias V.
    Leukemia; 1992 Apr 01; 6(4):295-303. PubMed ID: 1588792
    [Abstract] [Full Text] [Related]

  • 16. Immunologic and clinical modifications following low-dose subcutaneous administration of rIL-2 in non-Hodgkin's lymphoma patients after autologous bone marrow transplantation.
    Lauria F, Raspadori D, Ventura MA, Rondelli D, Zinzani PL, Gherlinzoni F, Miggiano MC, Fiacchini M, Rosti G, Rizzi S, Tura S.
    Bone Marrow Transplant; 1996 Jul 01; 18(1):79-85. PubMed ID: 8831999
    [Abstract] [Full Text] [Related]

  • 17. Functional and phenotypic modifications induced by IL-4, as single agent or in combination with IL-2, on PBMC preactivated in vivo by alpha-interferon + interleukin-2 therapy.
    Favrot M, Capdeville R, Combaret V, Zhou DC, Clapisson G, Banchereau J, Franks CR, Chouaib S, Blay JY, Philip T.
    Eur Cytokine Netw; 1990 Jul 01; 1(3):141-7. PubMed ID: 2129798
    [Abstract] [Full Text] [Related]

  • 18. Cell membrane expression and functional role of the p75 subunit of interleukin-2 receptor in lymphoproliferative disease of granular lymphocytes.
    Zambello R, Trentin L, Pizzolo G, Bulian P, Masciarelli M, Feruglio C, Agostini C, Raimondi R, Chisesi T, Semenzato G.
    Blood; 1990 Nov 15; 76(10):2080-5. PubMed ID: 2146981
    [Abstract] [Full Text] [Related]

  • 19. Recombinant interleukin-2 and lymphokine-activated killer cells in renal cancer patients: I. Phenotypic and functional analysis of the peripheral blood mononuclear cells.
    Fortis C, Ferrero E, Besana C, Biffi M, Heltai S, Galli L, Borri A, Schoenheit A, Rugarli C.
    Cancer Immunol Immunother; 1990 Nov 15; 32(3):161-6. PubMed ID: 2289209
    [Abstract] [Full Text] [Related]

  • 20. Clinical and immunologic effects of prolonged infusion of low-dose recombinant interleukin-2 after autologous and T-cell-depleted allogeneic bone marrow transplantation.
    Soiffer RJ, Murray C, Cochran K, Cameron C, Wang E, Schow PW, Daley JF, Ritz J.
    Blood; 1992 Jan 15; 79(2):517-26. PubMed ID: 1730094
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 35.